Stocks to Watch: MiMedx Group, Nokia
2023年12月30日 - 8:39AM
Dow Jones News
By Ben Glickman
MiMedx Group said on Friday it received an FDA warning letter
related to the classification of its product Axiofill. The
regulator has reaffirmed that the company's treatment doesn't
qualify as a Section 361 product, meaning it likely requires
pre-market review. Shares fall 6.5% to $8.20 after-hours.
Nokia expects to miss its 2023 financial outlook as
license-renewal discussions stretch into 2024. The company expects
to miss guidance on net sales, comparable operating margin and free
cash flow, and can't provide preliminary financial results for the
quarter because the reporting period hasn't concluded. Shares fall
1.5% to $3.37 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 29, 2023 18:24 ET (23:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Nokia (NYSE:NOK)
過去 株価チャート
から 4 2024 まで 5 2024
Nokia (NYSE:NOK)
過去 株価チャート
から 5 2023 まで 5 2024